Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 4,060,000 shares, an increase of 9.7% from the November 15th total of 3,700,000 shares. Based on an average daily volume of 520,300 shares, the short-interest ratio […]
CAMBRIDGE, Mass., Dec. 07, 2023 Fulcrum Therapeutics, Inc.® , a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.